a generic consequence of the network architecture in its present form. Finally, although some recent population-level studies have found reliable, internally generated, time-varying activity patterns that could be used for timing 15 , these take the form of sequential propagation of slow phasic responses across the neurons of a local network, a feature that, again, is not a generic property of the present architecture. Further work should strengthen the biological plausibility of the present results and their connection to the neurobiology of timing. Despite these open questions, however, the network devised by Laje and Buonomano 2 presents an excellent example of how the dynamics of simple neural networks can implement highly nontrivial computations in a robust fashion. Like time itself, our fascination with the dynamics of simple neural circuits only appears to progress.
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design, a very specific learning procedure is needed to produce them. The power of this approach, however, is that, once a stable trajectory is learned, it can be used to generate a variety of temporally structured outputs by training a variety of different output units. Second, the network considered is composed of firing rate units, whereas real neurons emit spikes. This is not merely a cosmetic detail. Although spiking networks can display chaotic behavior 13, 14 , their temporal fluctuations are generally much faster than those in firing rate models 13 . It is not clear how to extend the current approach to spiking networks. Third, the learning rule 11, 12 is very complex and not biologically implementable (for example, it is heavily nonlocal). It remains to be shown that more plausible learning rules can lead to qualitatively similar behavior. Fourth, a hallmark of timing behavior is the so-called scalar property 1 . Although, for certain parameters, the present model was able to accommodate a weaker version of this principle, it is not cresting the aLs mountain Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that primarily affects motor neurons of the brain and spinal cord. Whereas about 10% of ALS cases are familial (caused by a genetic mutation inherited from one's parents), most are sporadic in nature. Although recent studies have made inroads into unraveling the genomic architecture of the familial form of this disease, only a small fraction of sporadic cases can be attributed to a known genetic factor. In the Brief Communication from Chesi et al. 1 appearing in this issue of Nature Neuroscience, the authors used trio analysis ( Fig. 1) to identify de novo variants potentially underlying ALS, finding a mutation in the chromatin regulator SS18L1, also known as CREST.
To uncover de novo variants that may contribute to disease, the authors undertook exome sequencing in 47 ALS trios from North America, each comprising an affected proband with sporadic ALS and both unaffected parents. This elegant and relatively new genetic approach has proven fruitful in developmental and psychiatric conditions, such as autism spectrum disorder and schizophrenia 2, 3 . Lending credence to this approach, several investigators have identified a handful of ALS patients carrying de novo mutations in FUS and SOD1, genes already known to be pathogenic [4] [5] [6] . Until now, however, no one had systematically looked across the genome to discover new disease-associated genes.
Using this formidable genomic approach, Chesi et al. 1 pinpointed 25 genes that each harbor a previously unreported, hetero zygous, non-synonymous, de novo variant. Although 12 trios carried a single variant, 6 harbored more than one hit. Annotation analysis indicated that the 25 genes carrying de novo mutations were significantly enriched for chromatin regulators, with 5 encoding proteins involved in this pathway. Applying the same technique to exome sequence data suggested that this enrichment was ALS specific 2 .
Despite the prospective riches residing in these data, not all coding de novo variants are necessarily pathogenic. Thus, the authors sought to functionally characterize one of these chromatin regulators, SS18L1. They chose this particular gene because one of the trio probands harbored a premature stop variant at codon 388 that was predicted to be detrimental to the encoded protein. Examination of exome sequence data from 62 cases of familial ALS revealed a patient carrying a missense variant in CREST. This alteration was absent in public databases and in nearly 700 control individuals screened. Such validating genetic evidence in multiple ALS and control cohorts is essential, as the sporadic nature of these trios prevents any attempt to determine whether a genetic variant segregates with the disease phenotype across the family of interest.
To investigate the result of these CREST variants, the team leveraged the role of the protein in the neuron-specific chromatin remodeling complex nBAF, which regulates activity-induced dendrite outgrowth 7 . Transient transfection of primary mouse neurons with wild-type Crest had little effect on potassium chloride-induced dendrite outgrowth. However, expressing mutant Crest (the mouse ortholog of human CREST 1-388 ) significantly inhibited dendrite outgrowth in this system. These functional data demonstrate that expression of the observed CREST variants causes neuronal dysfunction.
npg n e w s a n d v i e w s our understanding of the commoner, sporadic form of ALS had come from mutational screening of familial genes identified elsewhere. This underscores the importance of the genetic data reported by Chesi et al. 1 They open the treasure chest of unresolved sporadic ALS by directly screening sporadic cases, independent of our existing knowledge of familial genes. We believe that similar sequencing approaches will yield further riches in the near future.
So where do we go from here? And what of the other 24 de novo variants detected in this study? The authors suggest sequencing these hits in larger patient populations. Indeed, large sequencing studies will form the bedrock for elucidating the unresolved genomic architecture of ALS. Certainly more genes will be found, and some of the variants described here may well be validated. Chesi et al. 1 have mined the first vein, but undoubtedly many others await discovery.
The authors bolstered the notion that CREST variants are pathogenic by showing that mouse Crest and Fus proteins interact in vivo. The importance of this observation stems from the fact that mutations in FUS account for approximately 4% of familial ALS, and these individuals develop FUS-positive neuronal cytoplasmic inclusions 8, 9 . Using mass spectrometry, Chesi et al. 1 detected Fus protein associated with nBAF complexes purified from mouse primary neurons. Immunoprecipitation analyses in nuclear lysates extracted from the same neuronal type demonstrated physical interaction between Crest and Fus.
Previous work in the literature, including reports from the same research group, has examined prion-like domains in proteins associated with neurodegenerative diseases. These domains may regulate pathogenic aggregation 10, 11 . Such permissive templating might also help explain the apparent spread of pathological changes seen in several conditions, including Parkinson's disease, Alzheimer's disease and ALS 12 . The new results further contribute to this hypothesis, as bioinformatic analyses predicted 1 that CREST contains prion-like domains.
Much remains to be understood about the role of chromatin modification in ALS. Histone deacetylase inhibitors have shown partial success at reducing motor neuron death and motor dysfunction in ALS mouse models 13 . Furthermore, histone acetylation is now recognized as a critical component of memory formation 13 . Given that mice carrying mutations in the nBAF subunit Baf53b show deficits in synaptic plasticity 14 , one could speculate that variants in CREST or another nBAF component might cause the related neurodegenerative condition frontotemporal dementia. Indeed, the authors point out that several of the identified de novo variants fit into a growing narrative describing mutations in nBAF subunits and other chromatin regulator genes that underlie human syndromes characterized by cognitive impairment and/or psychiatric features 15 . However, the lack of genetic validation for the other chromatin regulators uncovered in this new study advises caution before concluding that chromatin dysregulation is an overarching mechanism contributing to ALS pathogenesis.
The detected interaction between Crest and Fus is potentially of great importance, but many questions need to be answered. Is this interaction recapitulated in humans? Is it affected by the observed CREST variants? Does CREST colocalize with FUS in ALS inclusions? If so, might this mislocalization perturb normal nBAF chromatin remodeling activity, and could this outcome be central to the pathogenesis of CREST-linked ALS? A related question is whether the protein's prion-like domain is involved in any of these effects. These critical issues await further investigation.
Although the genomic architecture of familial ALS is about two-thirds complete, sporadic ALS is still comparatively unresolved, with only about 11% explained. Until now, progress in Katie Vicari Figure 1 Exome sequencing of a disease trio to systematically identify de novo coding mutations. In this example pedigree, the affected offspring carries a heterozygous mutation (*) that is not present in either unaffected parent. 
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Little is known about the molecular and cellular mechanisms underlying acute and chronic itch. A new technique for silencing peripheral itch neurons defines two independent itch circuits that transmit signals to the CNS.
Be it a mosquito bite, an allergic rash or a brush with poison ivy, most people have experienced itch. These are examples of acute itch, which is defined as an unpleasant sensation that causes a desire to scratch. Now imagine what life would be like if the acute itch you experienced were to spread over much of your body and be present every second of every day. Indeed, this is what patients suffering from chronic itch describe and why chronic itch has an effect on quality of life comparable to that of chronic pain. Chronic itch is devilishly difficult to treat, as current drugs and therapies are ineffective. From Shakespeare's Troilus and Cressida to Dante's Inferno to the Book of Deuteronomy, intractable itch has been described as a horrible curse reserved for one's worst enemy. Unfortunately, chronic itch is widespread; it results from a wide variety of pathological conditions, including eczema, kidney failure, cirrhosis, nervous system npg
